The work, led by Jianzhao Liu and Xin-Hua Feng of Zhejiang University together with colleagues at Soochow University and other Chinese institutions, began with a simple but technically demanding question: is METTL14, the scaffold subunit of the m6A methyltransferase complex, itself chemically modified? Using immunoprecipitation followed by immunoblotting in HEK293T and HeLa cells, the team found that METTL14, but not its catalytic partner METTL3 nor the regulatory subunit WTAP, is robustly ubiquitinated. Ubiquitin is best known as a destruction tag: chains linked through its lysine-48 residues deliver proteins to the proteasome. But ubiquitin can be assembled into eight distinct chain types, and several of them, including K27-linked chains, are thought to modulate protein interactions and localization rather than stability. When the researchers restricted cellular ubiquitin to single-linkage variants, METTL14’s modification turned out to be dominated by exactly this noncanonical K27 linkage.

Mass spectrometry then mapped the modification to specific lysine residues on METTL14, including lysines 148 and 278, positions that sit near the interfaces through which METTL14 grips its partners. To find the enzyme responsible, the team pulled down METTL14 and searched its associated proteins for candidate E3 ubiquitin ligases. The screen converged on RLIM, also known as RNF12, a RING-domain ligase first characterized as a corepressor of LIM homeodomain transcription factors. RLIM’s catalytic activity proved essential: a ligase-dead H569A/C572A mutant or a construct lacking the RING domain entirely failed to promote METTL14 ubiquitination, whereas wild-type RLIM drove robust K27-linked tagging in cells and in reconstituted in vitro reactions with defined E1 and E2 enzymes.

What makes this finding conceptually striking is what the ubiquitin mark does not do. RLIM knockout did not alter METTL14 protein abundance, and immunofluorescence showed that METTL14 still entered the nucleus normally in cells lacking RLIM. Instead, the modification acted on function. In vitro methylation assays demonstrated that K27-ubiquitinated METTL3–METTL14 complexes were markedly impaired in their ability to methylate RNA substrates. Two mechanisms accounted for the deficit. First, structural modeling and biochemical assays indicated that ubiquitin conjugated at lysine 278 distorts the loop regions at the METTL3–METTL14 interface, weakening the heterodimer that constitutes the active writer. Second, electrophoretic mobility shift assays and microscale thermophoresis showed that ubiquitinated or ubiquitination-mimicking complexes bound RNA less tightly, reducing substrate engagement. A split Nano-Luciferase reporter confirmed in living cells that RLIM expression disrupts METTL3–METTL14 association. In other words, RLIM acts as a rheostat on the writer’s activity rather than a trigger for its disposal.

The physiological consequence was visible across the transcriptome. MeRIP-seq and RNA-seq comparisons of control and RLIM-knockout cells revealed widespread hypermethylation of mRNA m6A peaks when RLIM was absent, with the affected transcripts enriched for genes governing the G2/M transition of the cell cycle. Consistent with known links between m6A and mRNA stability, hypermethylated transcripts in RLIM-knockout cells showed shortened half-lives, and many overlapped with binding targets of the m6A reader YTHDF2, which routes methylated transcripts toward degradation. Representative loci such as E4F1 and RHOB, both implicated in cell-cycle control, gained m6A and lost stability when RLIM was removed, and MeRIP-qPCR validated these changes independently.

The cell-cycle connection then became explicit. When the researchers synchronized cells by double thymidine block and released them, they observed coordinated periodic oscillations in three quantities: transcriptome-wide m6A levels, the intensity of K27-linked ubiquitin on METTL14, and RLIM protein abundance. RLIM knockout arrested cells at the G2/M boundary, an effect that could be rescued by knocking down METTL14, placing RLIM upstream of the writer in a pathway that governs mitotic entry. Measurements of global m6A-to-A ratios by LC-MS/MS across G1/S, S, G2, M and G1 phases confirmed that the methylation landscape rises and falls with the cycle, and immunofluorescence for phospho-histone H3 showed RLIM levels dropping precisely in mitotic cells.

The mechanism behind RLIM’s own oscillation turned out to be a classic mitotic kinase. The CDK1–cyclin B1 complex, the master switch for mitotic entry, physically associated with RLIM and phosphorylated it. Phosphatase treatments and Ser/Thr-to-Ala mutant analysis identified the phosphorylation sites responsible, and these modifications triggered RLIM to ubiquitinate itself with K48-linked chains, condemning it to proteasomal degradation. Blocking CDK1 or cyclin B1 by RNA interference stabilized RLIM, while proteasome inhibition with MG132, but not lysosomal inhibition with chloroquine, rescued the protein. This arrangement creates an elegant feedback loop: as CDK1–cyclin B1 surges at G2/M, it destroys RLIM, which releases METTL14 from inhibitory ubiquitination, allowing the writer complex to reassemble and retune the m6A landscape for the next phase of the cycle.

To test whether this axis matters beyond cultured cells, the team turned to animal and clinical models. In mice with Rlim deleted specifically in the myeloid lineage, bone marrow cells showed elevated m6A methylation on cell-cycle and differentiation genes, and flow cytometry revealed perturbed hematopoietic populations, effects that intensified after vesicular stomatitis virus infection. Endogenous METTL14 in these marrow cells lost its K27-linked ubiquitination, confirming the pathway operates in primary tissue. The researchers also examined MOLM-13, an acute myeloid leukemia cell line, where RLIM knockdown altered cell-cycle distribution and myeloid differentiation markers and reduced colony formation. Most compellingly, samples from patients with acute monocytic leukemia, collected through collaborating hospitals in Suzhou, displayed dysregulation of the RLIM–METTL14 axis, linking the molecular circuit to human disease.

The study’s broader significance lies in expanding the vocabulary of epitranscriptomic regulation. For a decade, the m6A writer has been viewed largely as a stable assembly whose output is tuned by accessory proteins, substrate availability and chromatin state. This work adds a temporal dimension: a cell-cycle-programmed, noncanonical ubiquitin code that switches the writer’s activity on and off without touching its concentration. Because K27-linked chains are increasingly recognized as scaffolds for protein–protein interactions in cell-cycle and quality-control pathways, the finding suggests that other RNA-processing enzymes may carry similar non-degradative marks awaiting discovery. It also reframes ubiquitin ligases, traditionally studied in the context of protein turnover, as direct modulators of the epitranscriptome.

Therapeutically, the implications are tantalizing but preliminary. Acute myeloid leukemia has already emerged as a disease exquisitely sensitive to m6A dosage, with the writer METTL3, the erasers FTO and ALKBH5, and the reader YTHDF2 each implicated in leukemic self-renewal. The new axis adds RLIM, and the CDK1–cyclin B1 switch that controls it, to the list of potential intervention points. CDK1 inhibitors are already in clinical use for other indications, raising the possibility that modulating RLIM stability could tune m6A levels in leukemia cells. For now, the study stands as a demonstration that the cell’s division clock reaches deep into its RNA chemistry, and that a ubiquitin tag once dismissed as obscure may be one of the hands on that clock.

Subject of Research: Cell-cycle-regulated noncanonical K27-linked ubiquitination of METTL14 controlling mRNA m6A methylation

Article Title: Cell-cycle-driven noncanonical ubiquitination of METTL14 orchestrates RNA methylation

Article References: Cao, J., Ying, X., Zhou, L., Zhang, Q., Huang, C., Dai, T., Shu, X., Gao, M., Mi, Y., Wu, X., Wang, F., Zhang, L., Zhou, F., Feng, X.-H., & Liu, J. (2026). Cell-cycle-driven noncanonical ubiquitination of METTL14 orchestrates RNA methylation. Nature Chemical Biology. https://doi.org/10.1038/s41589-026-02328-5

Image Credits: AI Generated

DOI: 10.1038/s41589-026-02328-5

Keywords: m6A, METTL14, RLIM, ubiquitination, K27-linked ubiquitin, cell cycle, CDK1, cyclin B1, epitranscriptomics, RNA methylation, acute myeloid leukemia, post-translational modification

The review begins by cataloguing the mechanical abnormalities that define the solid tumor microenvironment. Desmoplastic tumors, such as pancreatic ductal adenocarcinoma, deposit dense stromal matrix rich in collagen, crosslinked in part by enzymes like lysyl oxidase, producing tissue that can be far stiffer than healthy surrounding tissue. Growing cell masses generate solid stress that compresses blood and lymphatic vessels, raising interstitial fluid pressure and distorting fluid flow. Cancer-associated fibroblasts amplify this stiffness by contracting the matrix and depositing new extracellular material. These physical cues are not passive background conditions; cells sense them through integrin-based adhesions, mechanosensitive ion channels, and cytoskeletal networks, converting mechanical information into biochemical signals that reach all the way into the nucleus and alter gene expression.

The canonical mechanotransduction pathways described in the review provide plausible routes by which physical forces could reach the RNA modification machinery. Integrin-focal adhesion kinase signaling couples matrix rigidity to downstream cascades including PI3K-AKT, MAPK, and Rho-associated kinase pathways. The transcriptional coactivators YAP and TAZ, which respond to substrate stiffness and cytoskeletal tension, shuttle into the nucleus under mechanical loading and reprogram transcription. The stretch-activated ion channel PIEZO1 converts membrane tension into calcium influx, triggering downstream signaling. Cytoskeletal remodeling and nuclear deformation, mediated in part by LINC complexes that physically connect the cytoskeleton to the nuclear interior, can even alter chromatin organization directly. Each of these conduits, the authors argue, represents a potential input channel to the enzymes that write, erase, and read chemical marks on RNA.

Those enzymes are the heart of the epitranscriptome. N6-methyladenosine, or m6A, is the most abundant internal modification of messenger RNA and is installed by writer complexes containing METTL3, METTL14, and WTAP, removed by erasers such as FTO and ALKBH5, and interpreted by readers including YTHDF proteins and IGF2BP family members. Other modifications, including 5-methylcytosine, 7-methylguanosine, and pseudouridine, together with adenosine-to-inosine RNA editing, further diversify the informational content of the transcriptome. The review emphasizes that the activity, localization, and expression of these writers, erasers, and readers could plausibly be modulated by mechanical signaling. For example, YAP/TAZ-driven transcriptional programs could alter the expression levels of modification enzymes, while calcium influx through PIEZO1 could regulate enzymatic activity through calcium-dependent signaling, and nuclear deformation could influence where modification enzymes reside within the cell.

The most striking aspect of the review is its intellectual honesty about the state of the evidence. The authors applied a tiered classification to the studies they surveyed and found that only two investigations meet the strictest Tier-1 definition of mechanosensitive epitranscriptomics in cancer-relevant systems. The first is a study in pancreatic ductal adenocarcinoma showing that substrate stiffness influences the METTL14 and IGF2BP3 axis in a YAP1-dependent manner, linking matrix rigidity to m6A deposition and downstream oncogenic outputs. The second demonstrates that mechanical stiffness regulates the m6A eraser FTO in macrophages, thereby controlling Socs1 expression and shaping macrophage polarization, a process central to tumor immune dynamics. Most other reported connections between mechanics and RNA modification, the authors caution, remain Tier-3 hypotheses or associations potentially confounded by parallel changes in oxygen tension, inflammation, or metabolism that accompany altered mechanical environments.

Distinguishing direct mechanoregulation from these secondary effects is a central challenge the review confronts head-on. A stiff, hypoperfused tumor region is simultaneously stiff, hypoxic, nutrient-deprived, and inflamed. Hypoxia-inducible factors can independently regulate RNA modification enzymes, and inflammatory cytokines such as transforming growth factor beta do the same. To untangle this web, the authors propose testable experimental models: decoupling stiffness from hypoxia using engineered matrices, applying controlled mechanical stretch to cells in isolation, and using temporally precise perturbations to determine whether mechanical inputs causally drive changes in RNA modification rather than merely correlating with them. Such designs, they argue, are essential before the field can claim that mechanics acts directly on the epitranscriptomic machinery rather than through intermediary stress responses.

The tumor-immune interface is where the stakes of this framework become highest. Mechanical stress and RNA modifications jointly influence nearly every process that determines whether a tumor is recognized and destroyed by the immune system. Antigen presentation depends on the translation and processing of major histocompatibility complex components, processes that m6A and other modifications can tune. Interferon signaling, which alert neighboring cells to the presence of tumor antigens, is sensitive to RNA editing levels, since adenosine-to-inosine editing can alter how double-stranded RNA is perceived by innate immune sensors. Checkpoint molecules such as PD-L1 are themselves subject to RNA modification control. The review details how these regulatory layers could affect T-cell and natural killer cell function, the polarization of myeloid cells toward immunosuppressive fates, and the physical exclusion of immune cells from tumor nests, where stromal stiffness forms a mechanical barrier to immune infiltration.

On the translational side, the review outlines strategies for converting this framework into clinical tools. Magnetic resonance elastography already allows noninvasive mapping of tissue stiffness in patients, and combining such mechanical imaging with single-cell epitranscriptomic profiling, using methods like single-cell RNA sequencing, methylated RNA immunoprecipitation sequencing, and deamination-based modification mapping, could reveal how mechanical niches within tumors correspond to distinct RNA modification states. The authors envision composite biomarkers that integrate tumor mechanics, epitranscriptomic signatures, and predicted immunotherapy response, potentially identifying patients likely to benefit from immune checkpoint blockade. They also suggest that enzymes such as FTO, METTL14, or METTL3 could themselves become therapeutic targets, either alone or in combination with mechanical normalization strategies such as drugs that reduce matrix stiffness or stromal pressure, thereby softening the tumor microenvironment while simultaneously reprogramming RNA regulation.

What makes this review compelling is its refusal to overstate a young field. By explicitly ranking the evidence and naming the two Tier-1 studies, the authors provide a benchmark against which future work can be measured, and they openly acknowledge that much of the mechanosensitive epitranscriptomic landscape in cancer remains hypothetical. Yet the framework they assemble is rich with testable predictions: that specific mechanotransduction channels converge on specific modification enzymes, that these enzymes modify specific transcript subsets governing immune recognition, and that disrupting these circuits could restore immune visibility to mechanically armored tumors. As sequencing technologies for RNA modifications grow faster and more precise, and as engineered matrices allow cleaner mechanical experiments, the coming years should reveal whether the convergence of tumor mechanics and RNA chemistry is a genuine biological axis or a seductive correlation. Either way, the review establishes a clear roadmap for finding out, and in doing so adds a provocative new dimension to the ongoing effort to understand why some tumors so successfully hide from the immune system.

Subject of Research: How tumor mechanics regulate RNA modifications and immune escape in cancer

Article Title: Mechanosensitive epitranscriptomics in cancer: linking tumor mechanics, RNA modification, and immune escape

Article References: Jiang, M., Zhang, K., Li, M., Yao, J., Shi, R., Sun, C., Rodríguez, R. A., Lin, Z., Meng, J., Wang, Z., Wu, S., Luo, M., Zhang, W., Wei, R., Bai, Y., Lai, G., Zhang, C., Bo, Z., & Wang, T. (2026). Mechanosensitive epitranscriptomics in cancer: linking tumor mechanics, RNA modification, and immune escape. Molecular Cancer. https://doi.org/10.1186/s12943-026-02784-6

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02784-6

Keywords: mechanosensitive epitranscriptomics, RNA modifications, m6A, mechanotransduction, tumor microenvironment, immune escape, cancer immunotherapy, YAP/TAZ, METTL14, FTO, tumor stiffness, Molecular Cancer

Pancreatic alpha cells are best known as the body’s counterweight to insulin. While beta cells release insulin to lower blood glucose, alpha cells secrete glucagon, a hormone that raises blood sugar by mobilizing glucose stores from the liver. The tight coordination of these two hormones is fundamental to metabolic health, and its breakdown lies at the heart of both major forms of diabetes. Yet alpha cells have long lived in the shadow of their insulin-secreting neighbors. Only in recent years has the field come to appreciate that alpha cells possess their own finely tuned developmental program, a distinct epigenetic and transcriptional landscape, and a surprising capacity for plasticity, the ability to switch fate under certain pressures and transform into cells that resemble beta cells.

That plasticity is a double-edged sword. On one hand, it represents a tantalizing therapeutic opportunity: if the body’s own alpha cells can be coaxed into becoming functional beta cells, they could replace the insulin-producing cells destroyed or dysfunctional in diabetes. Previous work has shown that forced expression of transcription factors such as PDX1 and MAFA, delivered by viral gene therapy, can reprogram alpha cells into insulin-producing cells and even reverse autoimmune diabetes in mouse models. On the other hand, unplanned and incomplete fate conversion is potentially harmful. Cells caught between identities may perform neither function well, secreting inappropriate hormone combinations and destabilizing glucose control. Understanding the molecular brakes that normally prevent such drift is therefore as important as understanding the accelerators that drive it.

The new study identifies one of those brakes as a component of the cell’s RNA-processing equipment. N6-methyladenosine, commonly abbreviated m6A, is installed on mRNA by a multi-protein writer complex whose catalytic core includes the methyltransferase METTL14 together with its partner METTL3. The modification influences nearly every stage of an mRNA molecule’s life, including how it is spliced, exported from the nucleus, translated into protein, and eventually degraded. Because m6A affects the fates of thousands of transcripts simultaneously, it acts as a broad regulator of gene expression, shaping cell state without altering the underlying DNA sequence. Previous work had already shown that m6A methylation is required for human beta-cell identity and function, and that METTL14-dependent methylation governs early pancreatic endocrine differentiation, but the role of the modification in mature alpha cells remained unexplored.

To probe that question, the researchers deleted METTL14 specifically in alpha cells, stripping the cells of their capacity to deposit m6A marks on newly made mRNA. The consequences were immediate and instructive. Amino acid-stimulated glucagon secretion, the signature function of alpha cells, was impaired. Loss of the methylation machinery also destabilized the alpha-cell state itself: the expression of genes that define and sustain alpha-cell identity became disorganized, and the cells began to show features characteristic of immature, insulin-secreting, beta-cell-like fates. In other words, without its mRNA methylation marks, the alpha cell no longer reliably remembered what it was supposed to be.

The mechanistic logic is elegant. Alpha-cell identity is maintained by a network of transcription factors and regulatory RNAs whose balanced expression keeps the glucagon program active while repressing alternative fates. m6A methylation contributes to that balance by controlling the stability and translation of key transcripts. When METTL14 is lost, the methylation patterns that help enforce the alpha-cell program disappear, the network loses its grip, and plasticity pathways that are normally silenced can come to the fore. The result is a gradual shift in cell state, mirroring the fate conversions observed when developmental regulators are experimentally forced into action, but arising here from the absence of a housekeeping modification rather than the addition of a reprogramming factor.

These results extend a growing body of evidence that the epitranscriptome is not a passive decoration of RNA but an active pillar of cellular identity in the endocrine pancreas. The 2019 finding that m6A regulates human beta-cell biology in physiological states and in type 2 diabetes established the modification’s importance on the insulin-producing side of the islet. The new work completes the picture on the glucagon-producing side, showing that alpha cells depend on the same machinery to preserve their own specialized function. Together, the studies suggest that m6A methylation acts as a general safeguard of endocrine cell fate, protecting both major hormone-producing lineages of the pancreatic islet from identity erosion.

The implications for diabetes research are considerable. If loss of mRNA methylation promotes alpha-to-beta-like plasticity, then the modification could represent a checkpoint that regenerative therapies must either respect or deliberately manipulate. Strategies aimed at converting alpha cells into replacement beta cells might need to account for the destabilizing or stabilizing effects of the m6A machinery, and conversely, drugs that modulate m6A writers, erasers, or reader proteins could in principle be used to either encourage or restrain fate switching. More broadly, the work raises the possibility that some forms of islet dysfunction in diabetes may reflect age-related or stress-related decline in RNA modification pathways, a hypothesis that is now testable with the expanding toolkit of epitranscriptomic mapping methods.

The study also adds nuance to the concept of cellular plasticity itself. Rather than being triggered solely by external injury or forced transcription factor expression, fate drift can emerge from the quiet failure of an RNA-level maintenance system. This reframes alpha-cell identity as a state that must be actively and continuously renewed through post-transcriptional regulation, not merely switched on during development and left to run. The research team’s demonstration that METTL14 deletion simultaneously impairs amino acid-regulated glucagon secretion and promotes beta-like conversion links two previously separate observations, defective alpha-cell function and aberrant plasticity, into a single mechanistic framework.

For now, the immediate significance of the work is conceptual: it identifies mRNA methylation as a guardian of alpha-cell identity and provides a molecular explanation for how endocrine cells resist, or fail to resist, the pull of alternative fates. The long-term significance may prove larger. As the field continues to map the epitranscriptomic codes that stabilize or destabilize cell states, the prospect of precisely controlling cellular identity, whether to protect failing islets or to regenerate them, moves from speculation toward concrete pharmacology. The alpha cell, long considered a secondary player in diabetes biology, has now claimed a central role in that emerging story.

Subject of Research: The role of m6A mRNA methylation by METTL14 in maintaining pancreatic alpha-cell identity and preventing cellular plasticity toward beta-cell-like fates.

Article Title: mRNA methylation safeguards pancreatic α-cell identity against cellular plasticity

Article References: mRNA methylation safeguards pancreatic α-cell identity against cellular plasticity. (2026). Nature Metabolism. https://doi.org/10.1038/s42255-026-01594-w

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01594-w

Keywords: m6A methylation, METTL14, pancreatic alpha cells, epitranscriptomics, glucagon, cellular plasticity, beta cells, diabetes, gene regulation, RNA modification, islet biology, cell identity